Assessment of the risk of discontinuation of tenofovir disoproxil fumarate after delivery and the benefit of continued treatment in patients with immune tolerance
Postpartum discontinuation of TDF poses significant risks for immunotolerant pregnant women, whereas continuing TDF treatment for 144 weeks postpartum demonstrates favorable antiviral efficacy, bone and renal safety profiles.
Authors
- Minghua Su (ORCID: https://orcid.org/0000-0001-7831-6580)
- Haiping Liang (ORCID: https://orcid.org/0009-0000-6225-3394)
- Jianning Jiang (ORCID: https://orcid.org/0009-0005-1354-5127)
- Hengkai Liang
- Rongming Wang (ORCID: https://orcid.org/0000-0003-4075-6956)
- Bobin Hu (ORCID: https://orcid.org/0009-0008-4710-775X)
- Yanfei Feng
- Huan Liang
- Tumei Su
- Qingmei Li
- Linxian Huang
Institutions
- Guangxi Medical University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Guangxi Center for Disease Prevention and Control (CN)
- Tumor Hospital of Guangxi Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-11-07
- DOI
- https://doi.org/10.3389/fmed.2025.1597664
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Guangxi Medical University